https://www.biopharmawatch.com/news/HYFT/mindwalk-ai-biological-context-layer BiopharmaWatch en 2026-10-06T20:47:00.000Z MindWalk (NASDAQ : HYFT) : l'IA d'entreprise a trouvé sa couche ontologique, la biologie en a besoin d'une ancrée dans la fonction biologique https://www.biopharmawatch.com/news/BLCO/bausch-lomb-advances-oral-treatment-dry-amd BiopharmaWatch en 2026-10-06T20:30:00.000Z Bausch + Lomb Advances Novel Oral Treatment for Dry AMD Following Constructive FDA Meeting https://www.biopharmawatch.com/news/EHC/encompass-health-bangor-hospital-opening-maine BiopharmaWatch en 2026-10-06T20:30:00.000Z Encompass Health Rehabilitation Hospital of Bangor now open in Maine https://www.biopharmawatch.com/news/MMSI/merit-medical-systems-q3-2026-results-announcement BiopharmaWatch en 2026-10-06T20:30:00.000Z Merit Medical Systems to Announce Third Quarter 2026 Results on October 29, 2026 https://www.biopharmawatch.com/news/ALVO/alvotech-lotte-biologics-manufacturing-agreement BiopharmaWatch en 2026-10-06T20:30:00.000Z Alvotech and LOTTE Biologics announce US-based manufacturing agreement to increase global supply https://www.biopharmawatch.com/news/NVST/envista-third-quarter-2026-earnings-call BiopharmaWatch en 2026-10-06T20:15:00.000Z Envista Schedules Third Quarter 2026 Earnings Call https://www.biopharmawatch.com/news/CBIO/crescent-biopharma-announces-grants-inducement-awards-20261006 BiopharmaWatch en 2026-10-06T20:15:00.000Z Crescent Biopharma Announces Grants of Inducement Awards https://www.biopharmawatch.com/news/RCKT/rocket-pharmaceuticals-secures-credit-facility-150-million BiopharmaWatch en 2026-10-06T20:12:00.000Z Rocket Pharmaceuticals Secures Strategic Credit Facility for Up to $150 Million from Hercules Capital https://www.biopharmawatch.com/news/ARAY/accuray-stockholder-approval-financing-director BiopharmaWatch en 2026-10-06T20:10:00.000Z Accuray Announces Stockholder Approval of Key Financing-Related Proposals and Appointment of New Independent Director https://www.biopharmawatch.com/news/CRBU/caribou-biosciences-evaluate-strategic-alternatives BiopharmaWatch en 2026-10-06T20:05:31.000Z Caribou Biosciences to Evaluate Strategic Alternatives https://www.biopharmawatch.com/news/QGEN/qiagen-ai-powered-bioinformatics-research-drug-discovery BiopharmaWatch en 2026-10-06T20:05:00.000Z QIAGEN Expands AI-Powered Bioinformatics for Research and Drug Discovery https://www.biopharmawatch.com/news/BFLY/bridge-neurotech-butterfly-network-partnership-bci BiopharmaWatch en 2026-10-06T20:05:00.000Z Bridge Neurotech and Butterfly Network Announce Partnership to Develop Fully Non-Invasive Brain-Computer Interface https://www.biopharmawatch.com/news/MAZE/maze-therapeutics-mze829-mze782-asn-kidney-week-2026 BiopharmaWatch en 2026-10-06T20:05:00.000Z Maze Therapeutics to Present Data from MZE829 and MZE782 Programs at ASN Kidney Week 2026 https://www.biopharmawatch.com/news/EQ/equillium-poster-presentation-la-jolla-immunology-conference BiopharmaWatch en 2026-10-06T20:05:00.000Z Equillium Announces Poster Presentation at the 50th Anniversary La Jolla Immunology Conference https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-scientific-advisory-board-creation BiopharmaWatch en 2026-10-06T20:05:00.000Z Harvard Bioscience Announces Creation of Scientific Advisory Board https://www.biopharmawatch.com/news/IVA/inventiva-abstracts-aasld-liver-meeting-2026 BiopharmaWatch en 2026-10-06T20:05:00.000Z Inventiva présentera plusieurs abstracts scientifiques lors de l’AASLD The Liver Meeting® 2026 https://www.biopharmawatch.com/news/IVA/inventiva-present-scientific-abstracts-aasld-2026 BiopharmaWatch en 2026-10-06T20:05:00.000Z Inventiva to Present Scientific Abstracts at AASLD The Liver Meeting® 2026 https://www.biopharmawatch.com/news/HALO/halozyme-expands-collaboration-with-argenx-enhanze BiopharmaWatch en 2026-10-06T20:05:00.000Z Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx to Support the Development of Subcutaneous Formulations for Two Additional Exclusive Targets Using its ENHANZE® Technology https://www.biopharmawatch.com/news/ELVN/enliven-therapeutics-fda-alignment-enable-2-trial BiopharmaWatch en 2026-10-06T20:05:00.000Z Enliven Therapeutics Announces FDA Alignment on ENABLE-2 Phase 3 Trial Design for Relcobatinib (ELVN-001) in Previously Treated Chronic Myeloid Leukemia https://www.biopharmawatch.com/news/IMNM/immunome-reports-inducement-grants-nasdaq-listing-rule-5635-c-4-20261006 BiopharmaWatch en 2026-10-06T20:02:00.000Z Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/ACHV/achieve-life-sciences-announces-granting-new-hire-inducement-awards BiopharmaWatch en 2026-10-06T20:02:00.000Z Achieve Life Sciences Announces Granting of New Hire Inducement Awards https://www.biopharmawatch.com/news/BBIO/bridgebio-acoramidis-data-hfsa-annual-meeting-2026 BiopharmaWatch en 2026-10-06T20:01:00.000Z BridgeBio to Present New Acoramidis Data, Including Independent Comparative Real-World EHR Data at the HFSA Annual Scientific Meeting 2026 https://www.biopharmawatch.com/news/BBIO/bridgebio-present-evidence-phase-3-calibrate-trial-encaleret BiopharmaWatch en 2026-10-06T20:01:00.000Z BridgeBio to Present Additional Evidence from the Phase 3 CALIBRATE Trial of Encaleret in ADH1 at the ASBMR 2026 Annual Meeting https://www.biopharmawatch.com/news/EVGN/evogene-pure-capital-agreement-board-reconstitution BiopharmaWatch en 2026-10-06T20:00:00.000Z Evogene and Pure Capital Group Reach Cooperation Agreement to Resolve Differences and Reconstitute Board of Directors https://www.biopharmawatch.com/news/INAB/in8bio-inducement-grant-nasdaq-rule-5635c4 BiopharmaWatch en 2026-10-06T20:00:00.000Z IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/CDRE/veeva-dqs-nettoie-donnees-participants-etudes BiopharmaWatch en 2026-10-06T18:52:00.000Z Veeva DQS nettoie les données de plus d'un million de participants dans le cadre de plus de 1 000 études https://www.biopharmawatch.com/news/JUNS/jupiter-neurosciences-announces-first-patient-dosed-phase-2a-reset-trial BiopharmaWatch en 2026-10-06T15:15:00.000Z Jupiter Neurosciences Announces First Patient Dosed in Phase 2a RESET Trial in Parkinson’s Disease and Exploration of Strategic Options to Maximize Shareholder Value https://www.biopharmawatch.com/news/MDT/blink-anesthesia-lindsay-boyle-vp-commercial-operations BiopharmaWatch en 2026-10-06T14:18:00.000Z Blink Anesthesia, maker of the TwitchView® quantitative neuromuscular monitor, names Medtronic veteran Lindsay Boyle VP of Commercial Operations https://www.biopharmawatch.com/news/PFE/pfizer-fourth-quarter-2026-dividend BiopharmaWatch en 2026-10-06T14:00:00.000Z Pfizer Declares Fourth-Quarter 2026 Dividend https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-new-cfo-kevin-lundquist BiopharmaWatch en 2026-10-06T13:20:00.000Z Outlook Therapeutics Highlights What the Appointment of New CFO Kevin Lundquist Means for the Company’s Next Chapter in Virtual Investor Discussion https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-reports-100-growth-cypath-lung-sales-through-third BiopharmaWatch en 2026-10-06T13:19:00.000Z bioAffinity Technologies Reports Over 100% Growth in CyPath® Lung Sales Through Third Quarter 2026 https://www.biopharmawatch.com/news/LEXX/glp-1-weight-loss-diabetes-transition-oral-medications BiopharmaWatch en 2026-10-06T13:15:24.000Z GLP-1 Weight-Loss/Diabetes Industries Continue Transition to Oral Medications https://www.biopharmawatch.com/news/ASND/ascendis-advances-hypoparathyroidism-achondroplasia-asbmr-2026 BiopharmaWatch en 2026-10-06T13:15:00.000Z Ascendis to Share Latest Advances in Hypoparathyroidism and Achondroplasia Programs at ASBMR 2026 https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-midwest-dental-agreement BiopharmaWatch en 2026-10-06T13:07:00.000Z Dentsply Sirona Continues North American Commercial Expansion with Midwest Dental Agreement https://www.biopharmawatch.com/news/RGEN/repligen-acquisition-biolife-solutions BiopharmaWatch en 2026-10-06T13:05:00.000Z Repligen Completes Acquisition of BioLife Solutions https://www.biopharmawatch.com/news/NTHI/neonc-fda-catalyst-nthi-jolt BiopharmaWatch en 2026-10-06T13:02:00.000Z NeOnc’s FDA Catalyst Run Could Give NTHI a Serious Jolt https://www.biopharmawatch.com/news/DXCM/dexcom-u-season-5-record-roster-diabetes-stigma BiopharmaWatch en 2026-10-06T13:00:00.000Z Dexcom U Enters Season 5 With a Record Roster and Evidence That Diabetes Stigma Among Young Athletes Is Fading https://www.biopharmawatch.com/news/BDX/bdx-65-years-manufacturing-innovation-canaan BiopharmaWatch en 2026-10-06T13:00:00.000Z BD Celebrates 65 Years of Manufacturing, Innovation and Community Partnership in Canaan https://www.biopharmawatch.com/news/CODX/co-diagnostics-showcase-codx-pcr-platform-ebola-assay BiopharmaWatch en 2026-10-06T13:00:00.000Z Co-Diagnostics to Showcase Co-Dx PCR Platform* and MTB Test at WHX Labs Johannesburg, Highlight Ebola Assay Development https://www.biopharmawatch.com/news/PEN/storm-pe-data-wearable-technology-pulmonary-embolism BiopharmaWatch en 2026-10-06T13:00:00.000Z New STORM-PE Data Demonstrate Correlation Between Clinical Assessments and Real-world Functional Recovery Captured Through Wearable Technology in Patients with Pulmonary Embolism https://www.biopharmawatch.com/news/GILD/cognizant-expands-ai-devops-gilead-sciences BiopharmaWatch en 2026-10-06T13:00:00.000Z Cognizant Expands AI-Enabled DevOps Capabilities for Gilead Sciences https://www.biopharmawatch.com/news/INMB/inmune-bio-attend-2026-maxim-growth-summit BiopharmaWatch en 2026-10-06T13:00:00.000Z INmune Bio to Attend the 2026 Maxim Growth Summit https://www.biopharmawatch.com/news/MDLN/medline-third-quarter-2026-results-report BiopharmaWatch en 2026-10-06T13:00:00.000Z Medline to report third quarter 2026 results on November 4, 2026 https://www.biopharmawatch.com/news/ERNA/ernexa-therapeutics-erna-101-presentation-nature-conference BiopharmaWatch en 2026-10-06T12:55:00.000Z Ernexa Therapeutics’ ERNA-101 Selected for Flash Talk Presentation at Nature Conferences’ Next-Generation Cancer Therapeutics Meeting Co-Hosted by MD Anderson Cancer Center https://www.biopharmawatch.com/news/HYFT/mindwalk-biological-context-layer-ai-hyft BiopharmaWatch en 2026-10-06T12:46:00.000Z MindWalk (NASDAQ: HYFT): Enterprise AI Has Found Its Ontology Layer. Biology Needs One Grounded in Biological Function https://www.biopharmawatch.com/news/DWTX/dogwood-participate-2026-maxim-growth-summit BiopharmaWatch en 2026-10-06T12:45:00.000Z Dogwood to Participate in the 2026 Maxim Growth Summit https://www.biopharmawatch.com/news/NAGE/niagen-bioscience-ld-micro-20th-annual-event BiopharmaWatch en 2026-10-06T12:32:00.000Z Niagen Bioscience to Present at LD Micro 20th Annual Main Event https://www.biopharmawatch.com/news/OSTX/ost-therapies-phase-2b-trial-results BiopharmaWatch en 2026-10-06T12:30:00.000Z OS Therapies Achieves Statistically Significant Final Three-Year Overall Survival Benefit for Herlystic(TM)-Treated Patients in Phase 2b Pulmonary Metastatic Osteosarcoma Trial https://www.biopharmawatch.com/news/ACOG/alpha-cognition-present-zunveyl-data-ascp-meeting BiopharmaWatch en 2026-10-06T12:30:00.000Z Alpha Cognition to Present New ZUNVEYL® (Benzgalantamine) Clinical and Real-World Data at ASCP Annual Meeting and NEI Fall Congress https://www.biopharmawatch.com/news/HSCS/heartsciences-fda-clearance-myvista-wavecg-device BiopharmaWatch en 2026-10-06T12:30:00.000Z HeartSciences Receives FDA 510(k) Clearance for its MyoVista® wavECGTM Device https://www.biopharmawatch.com/news/IART/integra-lifesciences-q3-2026-financial-results-call BiopharmaWatch en 2026-10-06T12:30:00.000Z Integra LifeSciences to Host Third Quarter 2026 Financial Results Conference Call on October 21, 2026 https://www.biopharmawatch.com/news/CNXU/conexeu-sciences-fda-510k-submission-update BiopharmaWatch en 2026-10-06T12:30:00.000Z Conexeu Sciences Advances Ten Minute Tissue™ Toward Planned FDA 510(k) Submission https://www.biopharmawatch.com/news/MBOT/microbot-medical-medtechnica-distribution-agreement-israel BiopharmaWatch en 2026-10-06T12:30:00.000Z Microbot Medical® and Medtechnica Ltd. Enter into Three-Year Exclusive Distribution Agreement in Israel https://www.biopharmawatch.com/news/MDAI/spectral-ai-ntap-application-deepview-system BiopharmaWatch en 2026-10-06T12:30:00.000Z Spectral AI Submits New Technology Add-On Payment (NTAP) Application for DeepView™ System https://www.biopharmawatch.com/news/ICCM/icecure-expands-choices-study-low-risk-breast-cancer BiopharmaWatch en 2026-10-06T12:25:00.000Z IceCure Expands ProSense® ChoICE Study for Low-Risk Breast Cancer adding Legacy Health in Portland, OR as U.S. Clinical Site https://www.biopharmawatch.com/news/ARQT/arcutis-zoryve-wins-marie-claire-beauty-award BiopharmaWatch en 2026-10-06T12:20:26.000Z Arcutis’ ZORYVE® (roflumilast) Wins 2026 Marie Claire Beauty Award https://www.biopharmawatch.com/news/SXTP/60-degrees-pharmaceuticals-babesiosis-data-readout BiopharmaWatch en 2026-10-06T12:10:00.000Z 60 Degrees Pharmaceuticals Plans January 2027 Hospitalized Babesiosis Data Readout; Will Seek Pre-sNDA Meeting with FDA https://www.biopharmawatch.com/news/RKTO/rocket-one-patent-license-agreement-us-air-force BiopharmaWatch en 2026-10-06T12:05:00.000Z Rocket One Signs Patent License Agreement with U.S. Air Force for Technology Designed to Capture and Neutralize Hostile Drones https://www.biopharmawatch.com/news/ENTX/entera-appoints-laura-hamill-board-directors BiopharmaWatch en 2026-10-06T12:00:00.000Z Entera Appoints Global BioPharma Executive Laura Hamill to Its Board of Directors, Expanding Commercial Expertise https://www.biopharmawatch.com/news/COLL/collegium-start-talking-adhd-support-resources BiopharmaWatch en 2026-10-06T12:00:00.000Z Collegium Launches "Start Talking ADHD" with Practical Support to Help Families Navigate Care, School and Everyday Life https://www.biopharmawatch.com/news/PDSB/pds-biotech-kol-event-pds0301-colorectal-cancer BiopharmaWatch en 2026-10-06T12:00:00.000Z PDS Biotech to Host Key Opinion Leader Event on PDS0301 for the Treatment of Advanced Colorectal Cancer with Liver Metastases https://www.biopharmawatch.com/news/OABI/omniab-partner-pipeline-xploration-outlook BiopharmaWatch en 2026-10-06T12:00:00.000Z OmniAb Highlights Partner Pipeline, xPloration® Plans and Outlook, and Introduces the OmniTides™ Platform at Investor & Analyst Day https://www.biopharmawatch.com/news/NTRA/natera-signatera-data-astro-conference-2026 BiopharmaWatch en 2026-10-06T12:00:00.000Z New Signatera™ Data Presented at ASTRO Conference, Highlights Utility for Radiation Oncologists https://www.biopharmawatch.com/news/CRL/charles-river-autolomous-laboratory-execution-systems BiopharmaWatch en 2026-10-06T12:00:00.000Z Charles River and Autolomous Partner to Transform Laboratory Execution Systems https://www.biopharmawatch.com/news/AMLX/amylyx-phase-3-lucidity-trial-avexitide-obesityweek-2026 BiopharmaWatch en 2026-10-06T12:00:00.000Z Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting https://www.biopharmawatch.com/news/RVTY/revvity-host-investor-day-november-2026 BiopharmaWatch en 2026-10-06T12:00:00.000Z Revvity to Host Investor Day https://www.biopharmawatch.com/news/MCK/cdr-mckesson-acquire-option-care-health BiopharmaWatch en 2026-10-06T12:00:00.000Z CD&R and McKesson Corporation Sign Agreement to Acquire Option Care Health https://www.biopharmawatch.com/news/ENSG/diversified-healthcare-trust-ensign-group-lease-colorado BiopharmaWatch en 2026-10-06T12:00:00.000Z Diversified Healthcare Trust Announces 15-Year Net Lease with The Ensign Group for Colorado Skilled Nursing Portfolio https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-stk-002-aao-2026 BiopharmaWatch en 2026-10-06T12:00:00.000Z Stoke Therapeutics Announces Presentations of STK-002, an Investigational Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA), at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting https://www.biopharmawatch.com/news/TRLV/trulieve-q3-2026-results-conference-call BiopharmaWatch en 2026-10-06T12:00:00.000Z Trulieve Cannabis Corp. to Hold Third Quarter 2026 Results Conference Call on November 5, 2026 https://www.biopharmawatch.com/news/AVBP/arivent-phase-3-furvent-trial-update-firmonertinib BiopharmaWatch en 2026-10-06T12:00:00.000Z ArriVent Announces Program Update from the Phase 3 FURVENT Trial of Firmonertinib in First-Line EGFR Exon 20 Insertion Mutant NSCLC https://www.biopharmawatch.com/news/MDGL/madrigal-rezdiffra-efficacy-mash-genetic-variants BiopharmaWatch en 2026-10-06T12:00:00.000Z Madrigal Announces Publication in the Journal of Hepatology Demonstrating Consistent Rezdiffra Efficacy Across Common MASH Genetic Risk Variants https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-voice-trial-asn-kidney-week-2026 BiopharmaWatch en 2026-10-06T12:00:00.000Z Akebia Therapeutics Announces Late-Breaking VOICE Trial Presentation and Posters on Akebia’s Rare Kidney Pipeline at ASN Kidney Week 2026 https://www.biopharmawatch.com/news/LBRX/lb-pharmaceuticals-rd-day-lb-102-schizophrenia BiopharmaWatch en 2026-10-06T12:00:00.000Z LB Pharmaceuticals to Host In-Person and Virtual R&D Day on October 27, 2026: Advancing LB‑102 with a Focus on Schizophrenia Treatment https://www.biopharmawatch.com/news/YDES/yd-bio-eg-biomed-ai-cancer-risk-assessment BiopharmaWatch en 2026-10-06T12:00:00.000Z YD Bio and EG BioMed Launch AI-Based 10-Cancer Risk Factor Assessment https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-kol-event-hypoglycemia-type-1-diabetes BiopharmaWatch en 2026-10-06T12:00:00.000Z vTv Therapeutics to Host Virtual KOL Event on Hypoglycemia in Type 1 Diabetes and the Cadisegliatin Phase 3 Program on October 20, 2026 https://www.biopharmawatch.com/news/ODTX/odyssey-therapeutics-phase-2a-od-001-ueg-week-2026 BiopharmaWatch en 2026-10-06T12:00:00.000Z Odyssey Therapeutics Announces Oral Presentation of Additional Phase 2a Induction Data for OD-001 in Ulcerative Colitis at UEG Week 2026 https://www.biopharmawatch.com/news/TELO/telomir-pharmaceuticals-secures-financing-dejoria-investment BiopharmaWatch en 2026-10-06T12:00:00.000Z Telomir Pharmaceuticals Secures $5.6 Million Financing as Billionaire Entrepreneur John Paul DeJoria Increases Investment in the Company https://www.biopharmawatch.com/news/SYK/stryker-leadership-succession-announcement BiopharmaWatch en 2026-10-06T12:00:00.000Z Stryker announces leadership succession https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-aasld-liver-meeting-2026 BiopharmaWatch en 2026-10-06T12:00:00.000Z Galectin Therapeutics to Present at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2026 https://www.biopharmawatch.com/news/PTHS/pelthos-therapeutics-expanded-coverage-zelsuvmi BiopharmaWatch en 2026-10-06T12:00:00.000Z Pelthos Therapeutics Announces Expanded Formulary Coverage for ZELSUVMI® (berdazimer) Topical Gel, 10.3% https://www.biopharmawatch.com/news/BBIO/bridgebio-fda-acceptance-priority-review-infigratinib BiopharmaWatch en 2026-10-06T11:30:00.000Z BridgeBio Announces FDA Acceptance and Priority Review of NDA for Oral Infigratinib for Children with Achondroplasia https://www.biopharmawatch.com/news/KAPA/kairos-pharma-phase-2-trial-env-105-prostate-cancer BiopharmaWatch en 2026-10-06T11:30:00.000Z Kairos Pharma Reports Positive, Statistically Significant Interim Efficacy Data from Phase 2 Trial of ENV-105 in Metastatic Prostate Cancer https://www.biopharmawatch.com/news/DRIO/dariohealth-aon-analysis-healthcare-cost-reduction BiopharmaWatch en 2026-10-06T11:30:00.000Z DarioHealth Announces Independent Aon Analysis that Supports Estimated 2.5%-7.2% In-Year Reduction in Total Healthcare Costs https://www.biopharmawatch.com/news/ZBH/zimmer-biomet-webcast-q3-2026-results BiopharmaWatch en 2026-10-06T11:30:00.000Z Zimmer Biomet Announces Webcast and Conference Call of Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/BCTX/briacell-briapro-sitc-2026-poster-presentations BiopharmaWatch en 2026-10-06T11:30:00.000Z BriaCell and BriaPro to Present Four Posters at SITC 2026 Annual Meeting https://www.biopharmawatch.com/news/CNSY/cerenome-launches-cnside-csf-molecular-profile-tests BiopharmaWatch en 2026-10-06T11:30:00.000Z Cerenome Launches CNSide® CSF Molecular Profile Tests https://www.biopharmawatch.com/news/SCYX/scynexis-phase-1-study-results-scy-770-adpkd BiopharmaWatch en 2026-10-06T11:30:00.000Z SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-vk2735-maintenance-dosing-trial BiopharmaWatch en 2026-10-06T11:05:00.000Z Viking Therapeutics Announces Initiation of VK2735 Oral Maintenance Dosing Clinical Trial in Patients with Obesity https://www.biopharmawatch.com/news/PMN/promis-neurosciences-appoints-ivana-rubino-cco BiopharmaWatch en 2026-10-06T11:05:00.000Z ProMIS Neurosciences Appoints Seasoned Alzheimer’s and Neuroscience Executive Ivana Rubino, Ph.D., as Chief Commercial Officer https://www.biopharmawatch.com/news/ZBIO/zenas-biopharma-virtual-rd-event-october-2026 BiopharmaWatch en 2026-10-06T11:05:00.000Z Zenas BioPharma to Host Virtual R&D Event https://www.biopharmawatch.com/news/OCGN/ocugen-appoints-jolanda-crombach-european-affiliate BiopharmaWatch en 2026-10-06T11:02:00.000Z Ocugen Appoints Industry Executive Jolanda Crombach General Manager of European Affiliate https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-global-markets-virtual-forum-2026 BiopharmaWatch en 2026-10-06T11:00:00.000Z Phio Pharmaceuticals to Present at The Global Markets Virtual Forum October 8, 2026 https://www.biopharmawatch.com/news/REGN/regeneron-advances-cancer-care-esmo-2026 BiopharmaWatch en 2026-10-06T11:00:00.000Z Regeneron Showcases Advances in Care Across Several Cancers and Cancer-associated Complications at ESMO 2026 https://www.biopharmawatch.com/news/BRKR/draft-atlas-human-plasma-proteome BiopharmaWatch en 2026-10-06T11:00:00.000Z Untargeted timsTOF Mass Spectrometry Enables Discovery and Mapping of Draft Atlas of the Human Plasma Proteome at Proteoform Resolution https://www.biopharmawatch.com/news/BHC/bausch-health-third-quarter-2026-results BiopharmaWatch en 2026-10-06T11:00:00.000Z Bausch Health to Announce Third Quarter 2026 Results on October 28, 2026 https://www.biopharmawatch.com/news/CLGN/lightsolver-files-provisional-patent-photonic-computing BiopharmaWatch en 2026-10-06T11:00:00.000Z LightSolver Files U.S. Provisional Patent Application Expanding its Photonic Computing Platform to Advanced Scientific and Engineering Simulations https://www.biopharmawatch.com/news/CGEN/compugen-participate-fireside-chat-h-c-wainwright-3rd-annual-ai BiopharmaWatch en 2026-10-06T11:00:00.000Z Compugen to Participate in a Fireside Chat at the H.C. Wainwright 3rd Annual AI Based Drug Discovery & Development Conference https://www.biopharmawatch.com/news/MPLT/maplight-therapeutics-celebrates-dr-karl-deisseroth-nobel-prize BiopharmaWatch en 2026-10-06T11:00:00.000Z MapLight Therapeutics Celebrates Co-Founder Dr. Karl Deisseroth on Receipt of 2026 Nobel Prize in Physiology or Medicine for the Development of Optogenetics https://www.biopharmawatch.com/news/OKYO/okyo-phase-3-trial-urcosimod-neuropathic-corneal-pain BiopharmaWatch en 2026-10-06T11:00:00.000Z OKYO Pharma Announces First Patients Enrolled in Phase 3 Pivotal Trial of Urcosimod for Neuropathic Corneal Pain https://www.biopharmawatch.com/news/KMDA/kamada-expansion-biosimilars-portfolio-launch-products-israel BiopharmaWatch en 2026-10-06T11:00:00.000Z Kamada Announces Expansion of Biosimilars Portfolio with the Launch of Two Additional Products in Israel https://www.biopharmawatch.com/news/BDX/bd-appoints-ferass-abuzaina-president-surgery BiopharmaWatch en 2026-10-06T10:50:00.000Z BD Appoints Ferass Abuzaina as Worldwide President of Surgery https://www.biopharmawatch.com/news/TLX/first-patients-dosed-telix-pixclara-brain-cancer BiopharmaWatch en 2026-10-06T10:30:00.000Z First Patients Dosed with Telix’s FDA-Approved Brain Cancer Imaging Drug Pixclara® (floretyrosine F 18) https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-qrx003-dermatology-therapy BiopharmaWatch en 2026-10-06T10:30:00.000Z Quoin Pharmaceuticals Announces Acceptance of QRX003 Paper in Dermatology and Therapy https://www.biopharmawatch.com/news/MNOV/medicinova-participate-maxim-growth-summit BiopharmaWatch en 2026-10-06T10:00:00.000Z MediciNova to Participate in the Maxim Growth Summit https://www.biopharmawatch.com/news/SNN/smith-nephew-launch-cartiheal-agili-c-europe BiopharmaWatch en 2026-10-06T08:00:00.000Z Smith+Nephew lancia in Europa CARTIHEAL™ AGILI-C™, l’innovativo impianto per la riparazione della cartilagine, che sarà presentato all’ICRS Summit in Portogallo. https://www.biopharmawatch.com/news/SNN/smith-nephew-cartilage-repair-implant-launch-europe BiopharmaWatch en 2026-10-06T08:00:00.000Z Smith+Nephew’s revolutionary CARTIHEAL™ AGILI-C™ Cartilage Repair Implant launches in Europe; to be featured at ICRS Summit in Portugal https://www.biopharmawatch.com/news/MBX/microbix-presentation-cantech-investment-conference BiopharmaWatch en 2026-10-06T07:00:00.000Z Microbix Presenting at Cantech Investment Conference https://www.biopharmawatch.com/news/BJDX/bluejay-diagnostics-symon-ii-clinical-dataset-sepsis BiopharmaWatch en 2026-10-06T06:30:00.000Z Bluejay Diagnostics Announces SYMON-II Clinical Dataset Details Supporting Evaluation of Mortality Risk in Sepsis and Septic Shock https://www.biopharmawatch.com/news/TMO/thermo-fisher-new-solutions-cphi-milan-2026 BiopharmaWatch en 2026-10-06T06:00:00.000Z Thermo Fisher Scientific Showcases New Solutions and Expanded Capabilities to Accelerate Drug Development at CPHI Milan 2026 https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-350-million-public-offering BiopharmaWatch en 2026-10-06T00:13:00.000Z Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common Stock https://www.biopharmawatch.com/news/VOR/vor-bio-reports-inducement-grant-nasdaq-listing-rule-5635-c-20261005 BiopharmaWatch en 2026-10-05T22:00:00.000Z Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/PBYI/puma-biotechnology-inducement-award-nasdaq-rule-5635 BiopharmaWatch en 2026-10-05T21:00:00.000Z Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/PCVX/vaxcyte-public-offering-common-stock-notes BiopharmaWatch en 2026-10-05T20:28:00.000Z Vaxcyte Announces Commencement of Proposed Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes https://www.biopharmawatch.com/news/EQ/equillium-australian-regulatory-clearance-eq504-trial BiopharmaWatch en 2026-10-05T20:05:00.000Z Equillium Receives Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of EQ504 https://www.biopharmawatch.com/news/AGL/agilon-health-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-05T20:05:00.000Z agilon health Sets Date to Report Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/VIR/vir-biotechnology-expanded-phase-2-results-hepatitis-delta BiopharmaWatch en 2026-10-05T20:05:00.000Z Vir Biotechnology to Present Expanded Phase 2 SOLSTICE Results for Elebsiran and Tobevibart in Hepatitis Delta at AASLD’s The Liver Meeting® 2026 https://www.biopharmawatch.com/news/NEO/neogenomics-executive-leadership-succession-plan BiopharmaWatch en 2026-10-05T20:05:00.000Z NeoGenomics Announces Executive Leadership and Board of Directors Succession Plan https://www.biopharmawatch.com/news/BMRN/biomarin-appoints-cara-bauer-chief-people-officer BiopharmaWatch en 2026-10-05T20:05:00.000Z BioMarin Appoints Cara Bauer as Chief People Officer https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-presentation-kidney-week-2026 BiopharmaWatch en 2026-10-05T20:05:00.000Z Eledon Pharmaceuticals Announces Presentation at the American Society of Nephrology Kidney Week 2026 Annual Meeting https://www.biopharmawatch.com/news/KRRO/korro-phase-1-2-trial-krro-121 BiopharmaWatch en 2026-10-05T20:05:00.000Z Korro Announces First Cohort Dosed in Phase 1/2 Clinical Trial (ANCHOR) for KRRO-121 https://www.biopharmawatch.com/news/LAB/standard-bi-tools-sells-microfluidics-business-archimed BiopharmaWatch en 2026-10-05T20:05:00.000Z Standard BioTools Announces Agreement to Sell Microfluidics Business to ARCHIMED https://www.biopharmawatch.com/news/INSP/inspire-medical-systems-q3-2026-financial-results BiopharmaWatch en 2026-10-05T20:05:00.000Z Inspire Medical Systems, Inc. to Report Third Quarter 2026 Financial Results on November 2, 2026 https://www.biopharmawatch.com/news/ALMR/alamar-biosciences-bob-ragusa-board-appointment BiopharmaWatch en 2026-10-05T20:05:00.000Z Alamar Biosciences Names Former Grail CEO Bob Ragusa to Board of Directors and Expands Leadership Team https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-abstracts-liver-meeting-2026 BiopharmaWatch en 2026-10-05T20:05:00.000Z Aligos Therapeutics Announces Five Abstracts Accepted for Presentation at The Liver Meeting® 2026 https://www.biopharmawatch.com/news/VSTM/verastem-oncology-announces-inducement-grants-nasdaq-listing-rule-5635-c-20261005 BiopharmaWatch en 2026-10-05T20:02:00.000Z Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/BBIO/bridgebio-education-effort-attr-cm-awareness BiopharmaWatch en 2026-10-05T20:01:00.000Z BridgeBio and Community Partners Launch Nationwide ATTR-CM Education Effort Ahead of World Amyloidosis Day https://www.biopharmawatch.com/news/NGNE/neurogene-announces-inducement-grants-nasdaq-listing-rule-5635-c-4-20261005 BiopharmaWatch en 2026-10-05T20:01:00.000Z Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/GRAL/grail-new-data-nhs-galleri-pathfinder-2-edcc-esmo-2026 BiopharmaWatch en 2026-10-05T20:01:00.000Z GRAIL to Present New Data From NHS-Galleri and PATHFINDER 2 at EDCC and ESMO Congress 2026 https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-agreement-cancer-research-uk BiopharmaWatch en 2026-10-05T20:01:00.000Z ORIC® Pharmaceuticals Announces Agreement with Cancer Research UK to Advance a Potential First-in-Class CIP2A-Targeted Therapy Into Clinical Development https://www.biopharmawatch.com/news/CABA/cabaletta-bio-inducement-grants-nasdaq-rule-5635 BiopharmaWatch en 2026-10-05T20:01:00.000Z Cabaletta Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-announces-proposed-public-offering-common-stock BiopharmaWatch en 2026-10-05T20:01:00.000Z Spyre Therapeutics Announces Proposed Public Offering of its Common Stock https://www.biopharmawatch.com/news/ABBV/abbvie-genmab-announce-epcoritamab-combination-r-chop-demonstrates-significant-improvement BiopharmaWatch en 2026-10-05T18:54:00.000Z AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma https://www.biopharmawatch.com/news/GMAB/genmab-abbvie-epcoritamab-r-chop-trial-results BiopharmaWatch en 2026-10-05T18:50:00.000Z Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma https://www.biopharmawatch.com/news/ABBV/epcoritamab-r-chop-dlbcl-trial-results BiopharmaWatch en 2026-10-05T18:49:00.000Z Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma https://www.biopharmawatch.com/news/AZN/astrazeneca-opens-new-rd-center-kendall-square BiopharmaWatch en 2026-10-05T16:01:00.000Z AstraZeneca opens new global strategic R&D center in Kendall Square, Cambridge, Massachusetts https://www.biopharmawatch.com/news/HNGE/hinge-health-q3-2026-financial-results-announcement BiopharmaWatch en 2026-10-05T16:00:00.000Z Hinge Health to announce third quarter 2026 financial results on November 2, 2026 https://www.biopharmawatch.com/news/PRVA/anthem-blue-cross-privia-health-agreement-virginia BiopharmaWatch en 2026-10-05T15:49:00.000Z Anthem Blue Cross and Blue Shield in Virginia and Privia Health Reach New Agreement https://www.biopharmawatch.com/news/GH/guardant-health-cosmos-study-melanoma-recurrence BiopharmaWatch en 2026-10-05T15:27:00.000Z Guardant Health COSMOS Study Published in Cancer Research Communications Validates Utility of Guardant Reveal™ Liquid Biopsy Test for Predicting Recurrence in Melanoma https://www.biopharmawatch.com/news/AZN/serd-market-growth-2026-2036-astrazeneca-etcamah BiopharmaWatch en 2026-10-05T14:31:00.000Z SERD Market Set for Growth During the Forecast Period (2026-2036) as AstraZeneca's ETCAMAH Approval Accelerates Adoption of Oral SERDs | DelveInsight https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-positive-phase-1a-data-abi-6250 BiopharmaWatch en 2026-10-05T14:00:00.000Z Assembly Biosciences to Present Positive Phase 1a Safety, Tolerability and Target Engagement Data for ABI-6250 at AASLD The Liver Meeting® 2026 https://www.biopharmawatch.com/news/AIM/aim-immunotech-ampligen-antiviral-potential BiopharmaWatch en 2026-10-05T13:22:00.000Z AIM ImmunoTech Highlights Recent Media Coverage of Ampligen’s® Broad-Spectrum Antiviral and Biodefense Potential https://www.biopharmawatch.com/news/WAT/cellcarta-waters-partnership-companion-diagnostics BiopharmaWatch en 2026-10-05T13:15:00.000Z CellCarta Establishes Strategic Partnership with Waters to Advance Companion Diagnostics Development https://www.biopharmawatch.com/news/PHG/philips-sonicare-diamondclean-9900-prestige-launch BiopharmaWatch en 2026-10-05T13:00:00.000Z Philips Sonicare Next-Generation DiamondClean 9900 Prestige Is Now Available On Amazon; The Brand’s Most Advanced, Intelligent Toothbrush That Gives Users Real-Time Guidance Alongside Signature Brushing Performance https://www.biopharmawatch.com/news/CVS/cvs-health-third-quarter-2026-earnings-call BiopharmaWatch en 2026-10-05T13:00:00.000Z CVS Health to hold third quarter 2026 earnings conference call https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-hope-3-deramiocel-data BiopharmaWatch en 2026-10-05T13:00:00.000Z Capricor Therapeutics Presents Positive HOPE-3 Open-Label Extension Data on Upper Limb Function in Duchenne Muscular Dystrophy at 2026 World Muscle Society Congress https://www.biopharmawatch.com/news/IMMX/immix-biopharma-jp-morgan-healthcare-conference-2027 BiopharmaWatch en 2026-10-05T12:45:00.000Z Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare Conference https://www.biopharmawatch.com/news/NVO/novo-nordisk-s-share-repurchase-programme-20261005 BiopharmaWatch en 2026-10-05T12:32:00.000Z Novo Nordisk A/S – Share repurchase programme https://www.biopharmawatch.com/news/BEAT/heartbeam-fda-breakthrough-device-designation BiopharmaWatch en 2026-10-05T12:31:00.000Z HeartBeam Receives FDA Breakthrough Device Designation for Heart Attack Assessment https://www.biopharmawatch.com/news/AUTL/autolus-therapeutics-carlysle-trial-acr-convergence-2026 BiopharmaWatch en 2026-10-05T12:30:00.000Z Autolus Therapeutics to Present Longer-Term Follow Up Data from CARLYSLE Trial at the American College of Rheumatology Convergence 2026 https://www.biopharmawatch.com/news/TMO/thermo-fisher-proteomics-discovery-precise-sg100k BiopharmaWatch en 2026-10-05T12:30:00.000Z Thermo Fisher Scientific Proteomics Technologies Enable Discovery of More Than 2,500 New Biological Associations in PRECISE-SG100K Study https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-october-conferences BiopharmaWatch en 2026-10-05T12:30:00.000Z Aprea Therapeutics to Present at October Conferences https://www.biopharmawatch.com/news/BCAX/bicara-therapeutics-announces-inducement-grants-nasdaq-listing-rule-5635-c-20261005 BiopharmaWatch en 2026-10-05T12:30:00.000Z Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-first-case-stable-disease-three-months-ovarian BiopharmaWatch en 2026-10-05T12:15:00.000Z Anixa Biosciences Announces First Case of Stable Disease for Three Months in Ovarian Cancer CAR-T Clinical Trial https://www.biopharmawatch.com/news/ARDX/ardelyx-new-data-hyperphosphatemia-asn-kidney-week-2026 BiopharmaWatch en 2026-10-05T12:01:00.000Z Ardelyx to Present New Data on Hyperphosphatemia Management at ASN Kidney Week 2026 https://www.biopharmawatch.com/news/RVMD/revolution-medicines-phase-3-rasolute-309-trial BiopharmaWatch en 2026-10-05T12:00:34.000Z Revolution Medicines Begins Treating Patients in Phase 3 RASolute 309 Trial Evaluating RASONQUE™ (daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic RAS G12D Pancreatic Cancer https://www.biopharmawatch.com/news/PCRX/pacira-molteni-agreement-exparel-eu-uk BiopharmaWatch en 2026-10-05T12:00:03.000Z Pacira Announces Exclusive Agreement with Molteni Farmaceutici to Commercialize EXPAREL® in the European Union and United Kingdom https://www.biopharmawatch.com/news/RANI/rani-therapeutics-fda-emerging-technology-program BiopharmaWatch en 2026-10-05T12:00:01.000Z Rani Therapeutics Announces Acceptance into U.S. FDA's Emerging Technology Program (ETP) https://www.biopharmawatch.com/news/RADX/radiopharm-end-of-phase-2-fda-meeting-rad101 BiopharmaWatch en 2026-10-05T12:00:00.000Z Radiopharm Completes Productive End-of-Phase 2 Meeting with U.S. Food and Drug Administration for Pivotal Development Program of RAD101 https://www.biopharmawatch.com/news/BNTC/benitec-biopharma-regulatory-update-bb-301 BiopharmaWatch en 2026-10-05T12:00:00.000Z Benitec Biopharma Announces Regulatory Update Following Type C Meeting with FDA for BB-301 Pivotal Study https://www.biopharmawatch.com/news/ESTA/establishment-labs-receives-fda-approval-additional-sizes-motiva-implants BiopharmaWatch en 2026-10-05T12:00:00.000Z Establishment Labs® Receives FDA Approval for Additional Sizes of Motiva Implants® https://www.biopharmawatch.com/news/ELV/elevance-health-conference-call-q3-2026-results BiopharmaWatch en 2026-10-05T12:00:00.000Z Elevance Health to Hold Conference Call and Webcast to Discuss Third Quarter 2026 Results on October 21, 2026 https://www.biopharmawatch.com/news/BFLY/butterfly-network-appoints-mike-noonen-board BiopharmaWatch en 2026-10-05T12:00:00.000Z Butterfly Network Appoints Mike Noonen to Board of Directors https://www.biopharmawatch.com/news/COYA/coya-therapeutics-phase-2-3-alstars-trial-completion BiopharmaWatch en 2026-10-05T12:00:00.000Z Coya Therapeutics Announces Completion of Full Enrollment in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS https://www.biopharmawatch.com/news/GEHC/ge-healthcare-acquire-sofie-biosciences-pet-radiopharmaceuticals BiopharmaWatch en 2026-10-05T12:00:00.000Z GE HealthCare to Acquire SOFIE Biosciences, Establishing a 'Final Mile' Footprint for PET Radiopharmaceutical Supply in the U.S. https://www.biopharmawatch.com/news/NTRA/aft-70-navigate-global-randomized-phase-iii-trial BiopharmaWatch en 2026-10-05T12:00:00.000Z Alliance Foundation Trials and Natera Announce AFT-70 NAVIGATE: a Global, Randomized, Phase III Trial Evaluating Genentech’s Oral Selective Estrogen Receptor Degrader (SERD) with Signatera™ MRD-Guided CDK4/6 Inhibitor Therapy in Breast Cancer https://www.biopharmawatch.com/news/ICU/seastar-medical-warrant-exercise-3-3-million BiopharmaWatch en 2026-10-05T12:00:00.000Z SeaStar Medical Announces Exercise of Warrants for Approximately $3.3 Million Gross Proceeds https://www.biopharmawatch.com/news/FDMT/4dmt-investor-day-october-2026 BiopharmaWatch en 2026-10-05T12:00:00.000Z 4DMT to Host Investor Day on October 21, 2026 https://www.biopharmawatch.com/news/PMVP/pmv-pharmaceuticals-appoints-matt-eckler-board BiopharmaWatch en 2026-10-05T12:00:00.000Z PMV Pharmaceuticals Appoints Matt Eckler, Ph.D., to Board of Directors https://www.biopharmawatch.com/news/CELC/celcuity-esmo-congress-2026-presentations BiopharmaWatch en 2026-10-05T12:00:00.000Z Celcuity Announces Multiple Presentations At The European Society For Medical Oncology (ESMO) Congress 2026 https://www.biopharmawatch.com/news/LSTA/marea-therapeutics-phase-2-trial-mar002-acromegaly BiopharmaWatch en 2026-10-05T12:00:00.000Z Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-phase-3-catt1-study-completion BiopharmaWatch en 2026-10-05T12:00:00.000Z vTv Therapeutics Announces Completion of Enrollment in Phase 3 CATT1 Study of Cadisegliatin in Type 1 Diabetes (T1D) https://www.biopharmawatch.com/news/TELA/tela-bio-510k-clearance-liora-scaffold BiopharmaWatch en 2026-10-05T12:00:00.000Z TELA Bio Announces 510(k) Clearance for Liora™ Monofilament Scaffold for Soft Tissue Reinforcement https://www.biopharmawatch.com/news/HIND/vyome-usp-to-notice-allowance-vt-1908-patent BiopharmaWatch en 2026-10-05T12:00:00.000Z Vyome Receives USPTO Notice of Allowance for U.S. Patent Covering VT-1908, its Novel Topical Mycophenolate Program Targeting the $20+ Billion Ocular Inflammation Market https://www.biopharmawatch.com/news/PRME/prime-medicine-phase-1-2-trial-pm577a-wilson-disease BiopharmaWatch en 2026-10-05T11:59:59.000Z Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease https://www.biopharmawatch.com/news/LLY/lilly-dermatology-data-fall-clinical-2026 BiopharmaWatch en 2026-10-05T11:50:00.000Z Lilly to present new data across its dermatology portfolio with 21 presentations at Fall Clinical 2026, in pursuit of advancing care for chronic skin conditions https://www.biopharmawatch.com/news/HURA/tuhura-biosciences-us-patent-dor-technology BiopharmaWatch en 2026-10-05T11:45:00.000Z TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) Technology https://www.biopharmawatch.com/news/PLRZ/polyrizon-files-us-patent-intranasal-drug-delivery BiopharmaWatch en 2026-10-05T11:32:00.000Z Polyrizon Files for U.S. Patent Application to Expand IP Moat Around Intranasal Drug-Delivery Platform https://www.biopharmawatch.com/news/BBIO/bbp-418-potential-disease-modifying-therapy-lgmd2i-r9 BiopharmaWatch en 2026-10-05T11:30:00.000Z BBP-418 Demonstrates Potential to Be Disease Modifying Therapy, Restoring Cardiac and Disease Markers to Unaffected Levels https://www.biopharmawatch.com/news/BLCO/bausch-lomb-third-quarter-2026-results BiopharmaWatch en 2026-10-05T11:30:00.000Z Bausch + Lomb Will Release Third-Quarter 2026 Financial Results on Oct. 28 https://www.biopharmawatch.com/news/CBIO/crescent-biopharma-fda-clearance-ind-cr-002 BiopharmaWatch en 2026-10-05T11:30:00.000Z Crescent Biopharma Announces FDA Clearance of IND Application for CR-002, a PD-L1-targeted Topoisomerase Inhibitor ADC, for the Treatment of Solid Tumors https://www.biopharmawatch.com/news/MMED/minimed-smart-mdi-alerts-glucose-outcomes BiopharmaWatch en 2026-10-05T11:08:00.000Z Responding more frequently to MiniMed Smart MDI alerts linked to better glucose outcomes for people with diabetes https://www.biopharmawatch.com/news/HLF/herbalife-maxim-growth-summit-october-14 BiopharmaWatch en 2026-10-05T11:05:00.000Z Herbalife to Participate in 1 on 1 Meetings at Maxim Growth Summit on October 14 https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-ath434-phase-2-data-multiple-system-atrophy BiopharmaWatch en 2026-10-05T11:05:00.000Z Alterity Therapeutics Presents New Analyses of ATH434 Phase 2 Data in Multiple System Atrophy at the 2026 International Congress of Parkinson’s Disease and Movement Disorders https://www.biopharmawatch.com/news/IVVD/invivyd-inducement-grants-nasdaq-listing-rule BiopharmaWatch en 2026-10-05T11:01:00.000Z Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/INSM/insmed-cfo-transition-sara-bonstein BiopharmaWatch en 2026-10-05T11:00:00.000Z Insmed Announces CFO Transition https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-niba-conference-presentation BiopharmaWatch en 2026-10-05T11:00:00.000Z Phio Pharmaceuticals to Present at the National Investment Banking Association (NIBA) 153rd Conference https://www.biopharmawatch.com/news/PBM/psyence-biomeds-ibogaine-manufacturing-partnership BiopharmaWatch en 2026-10-05T11:00:00.000Z Psyence BioMed Partners with DEA-Registered Benuvia Operations to Establish U.S. Manufacture of Pharmaceutical-Grade Ibogaine https://www.biopharmawatch.com/news/ALEC/alector-genentech-license-agreement-parkinsons-disease BiopharmaWatch en 2026-10-05T11:00:00.000Z Alector Enters Global License Agreement with Genentech for Brain Penetrant GCase Enzyme Replacement Therapy for Parkinson’s Disease and Other Neurodegenerative Diseases https://www.biopharmawatch.com/news/MSLE/satellos-granted-patent-for-forazapadin BiopharmaWatch en 2026-10-05T11:00:00.000Z Satellos Granted Composition of Matter Patent for Forazapadin https://www.biopharmawatch.com/news/BCRX/biocryst-scientific-advisory-board-formation BiopharmaWatch en 2026-10-05T11:00:00.000Z BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth https://www.biopharmawatch.com/news/SMMT/astrazeneca-completes-2-billion-investment-summit-therapeutics BiopharmaWatch en 2026-10-05T11:00:00.000Z AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-fda-meeting-zorevunersen-dravet-syndrome BiopharmaWatch en 2026-10-05T11:00:00.000Z Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome https://www.biopharmawatch.com/news/IRIX/iridex-relocation-manufacturing-facility-san-jose BiopharmaWatch en 2026-10-05T11:00:00.000Z Iridex Completes Relocation of Manufacturing Facility to San Jose, California https://www.biopharmawatch.com/news/RZLT/rezolute-fda-pre-bla-meeting-ersodetug BiopharmaWatch en 2026-10-05T11:00:00.000Z Rezolute Announces FDA Recommendation to Hold a Pre-BLA Meeting as a Precursor to Submitting a Biologics License Application (BLA) for Congenital Hyperinsulinism https://www.biopharmawatch.com/news/HROW/harrow-acquires-tyrvaya-nasal-spray BiopharmaWatch en 2026-10-05T11:00:00.000Z Harrow Closes Acquisition of TYRVAYA® https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-research-term-extension-gilead BiopharmaWatch en 2026-10-05T11:00:00.000Z Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences https://www.biopharmawatch.com/news/VTRS/viatris-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-05T10:59:00.000Z Viatris to Report Third-Quarter 2026 Financial Results on November 5, 2026 https://www.biopharmawatch.com/news/PHVS/real-world-analysis-hai-disease-experience-treatment-gaps BiopharmaWatch en 2026-10-05T10:50:27.000Z Real-World Analysis Highlighting HAE Disease Experience and Gaps in Treatment Satisfaction Published in Advances in Therapy https://www.biopharmawatch.com/news/CMPS/compass-pathways-new-office-jersey-city BiopharmaWatch en 2026-10-05T10:30:00.000Z Compass Pathways Celebrates Opening of New U.S. Office in Jersey City, New Jersey https://www.biopharmawatch.com/news/FTRE/fortrea-third-quarter-2026-financial-results-call BiopharmaWatch en 2026-10-05T10:30:00.000Z Fortrea Announces Date for Third Quarter 2026 Financial Results and Conference Call https://www.biopharmawatch.com/news/EW/edwards-lifesciences-host-investor-event-tct BiopharmaWatch en 2026-10-05T10:00:00.000Z Edwards Lifesciences to Host Investor Event in Conjunction With TCT https://www.biopharmawatch.com/news/WST/west-highlight-industry-leadership-cphi-worldwide BiopharmaWatch en 2026-10-05T10:00:00.000Z West to Highlight Industry Leadership in Packaging and Containment at CPHI Worldwide https://www.biopharmawatch.com/news/PCVX/vaxcyte-opus-1-phase-3-trial-results BiopharmaWatch en 2026-10-05T10:00:00.000Z Vaxcyte Reports Positive Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate https://www.biopharmawatch.com/news/NNVC/nanoviricides-phase-ii-trial-nv-387-ebola BiopharmaWatch en 2026-10-05T08:45:00.000Z NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 Lives https://www.biopharmawatch.com/news/VBIO/valion-bio-chair-thomas-jensen-advancement-entolimod BiopharmaWatch en 2026-10-05T08:30:00.000Z New Valion Bio Board Chair Thomas Jensen Brings Biotech Turnaround Experience to the Advancement of Entolimod https://www.biopharmawatch.com/news/UTMD/utah-medical-products-extends-tender-offer BiopharmaWatch en 2026-10-05T08:30:00.000Z Utah Medical Products, Inc. Extends Tender Offer https://www.biopharmawatch.com/news/ALVO/fda-approves-additional-manufacturing-capacity-simlandi BiopharmaWatch en 2026-10-05T08:00:00.000Z FDA approves additional U.S. manufacturing capacity for SIMLANDI®, Alvotech’s biosimilar to Humira® https://www.biopharmawatch.com/news/BMY/help-save-a-life-blood-donation-drive-bmy BiopharmaWatch en 2026-10-05T07:54:00.000Z Driving Community Health: Bristol Myers Squibb, Emirates Thalassemia Society and Dubai Science Park Host the 6th 'Help Save a Life' Blood Donation Drive https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-champions-in-care-expansion BiopharmaWatch en 2026-10-05T07:29:00.000Z Bristol Myers Squibb Deepens Commitment to Healthcare Professionals Through Champions in Care Movement https://www.biopharmawatch.com/blog/biotech-catalysts-to-watch-week-of-2026-10-05 BiopharmaWatch en 2026-10-05T07:15:33.007Z SIL204 Phase 2/3 for Locally Advanced Pancreatic Cancer: Biotech Catalysts Oct 5, 2026